Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Stock Crosses Below 200-Day Moving Average - Here's Why

Novozymes A/S logo with Basic Materials background

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $60.22 and traded as low as $55.49. Novozymes A/S shares last traded at $58.72, with a volume of 9,063 shares trading hands.

Novozymes A/S Stock Down 9.1 %

The company has a market cap of $25.92 billion, a P/E ratio of 35.03, a PEG ratio of 3.87 and a beta of 0.91. The company has a 50 day moving average price of $58.18 and a 200-day moving average price of $59.96.

Novozymes A/S Increases Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Monday, April 7th will be paid a dividend of $0.3758 per share. This is a positive change from Novozymes A/S's previous dividend of $0.17. The ex-dividend date of this dividend is Monday, April 7th. Novozymes A/S's dividend payout ratio (DPR) is presently 47.47%.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Featured Articles

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in May 2025
3 Stocks Offering Rare Generational Buying Opportunities
Make Your Money Work Harder: The Power of Dividend Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines